Prednisone
- Generic Name
- Prednisone
- Brand Names
- Deltasone, Rayos, Winpred
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26O5
- CAS Number
- 53-03-2
- Unique Ingredient Identifier
- VB0R961HZT
- Background
A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.
Prednisone was granted FDA approval on 21 February 1955.
- Indication
Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.
- Associated Conditions
- Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis
- Associated Therapies
- Palliative Treatment
Mercaptopurine Therapy in Ulcerative Colitis
- Conditions
- Colitis, Ulcerative
- Interventions
- First Posted Date
- 2016-09-22
- Last Posted Date
- 2020-01-07
- Lead Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Target Recruit Count
- 136
- Registration Number
- NCT02910245
- Locations
- 🇳🇱
Meander MC, Amersfoort, Netherlands
🇳🇱Amstelland Hospital, Amsterdam, Netherlands
🇳🇱OLVG Oost, Amsterdam, Netherlands
Effect of Oral Steroids on Skin Outcomes in Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: Placebo ControlDrug: Prednisone
- First Posted Date
- 2016-09-21
- Last Posted Date
- 2018-08-20
- Lead Sponsor
- McMaster University
- Target Recruit Count
- 16
- Registration Number
- NCT02908698
- Locations
- 🇨🇦
McMaster University, Hamilton, Ontario, Canada
Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 118
- Registration Number
- NCT02903368
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸University of California, San Diego Moores Cancer Center, La Jolla, California, United States
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 40
- Registration Number
- NCT02903160
- Locations
- 🇺🇸
Mount Sinai Beth Israel, New York, New York, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
- Conditions
- B Acute Lymphoblastic Leukemia, BCR-ABL1-LikeB Acute Lymphoblastic LeukemiaCentral Nervous System LeukemiaTesticular Leukemia
- Interventions
- Drug: CyclophosphamideDrug: ClofarabineDrug: CytarabineDrug: Daunorubicin HydrochlorideDrug: DasatinibDrug: DexamethasoneDrug: EtoposideDrug: Doxorubicin HydrochlorideDrug: Hydrocortisone Sodium SuccinateDrug: Leucovorin CalciumOther: Laboratory Biomarker AnalysisDrug: MercaptopurineDrug: MethotrexateDrug: PegaspargaseDrug: ThioguanineDrug: Vincristine SulfateDrug: PrednisoneRadiation: Radiation Therapy
- First Posted Date
- 2016-08-30
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 5949
- Registration Number
- NCT02883049
- Locations
- 🇺🇸
Nemours Children's Hospital, Orlando, Florida, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
🇺🇸Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
- Conditions
- B Acute Lymphoblastic LeukemiaB Lymphoblastic Lymphoma
- Interventions
- Biological: BlinatumomabDrug: CyclophosphamideDrug: CytarabineDrug: DexamethasoneDrug: Doxorubicin HydrochlorideBiological: Inotuzumab OzogamicinOther: Laboratory Biomarker AnalysisDrug: MercaptopurineDrug: MethotrexateBiological: OfatumumabDrug: PrednisoneBiological: RituximabDrug: Vincristine Sulfate
- First Posted Date
- 2016-08-24
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 80
- Registration Number
- NCT02877303
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Serum FFA Desaturase Activity Index in Patients on High Dose Corticosteroids
- Conditions
- Glucocorticoid
- Interventions
- First Posted Date
- 2016-08-19
- Last Posted Date
- 2016-08-19
- Lead Sponsor
- Rambam Health Care Campus
- Target Recruit Count
- 20
- Registration Number
- NCT02872584
Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2016-08-15
- Last Posted Date
- 2021-07-07
- Lead Sponsor
- Latin American Cooperative Oncology Group
- Target Recruit Count
- 128
- Registration Number
- NCT02867020
- Locations
- 🇧🇷
Beneficiencia Portuguesa de São Paulo/Hospital São José, São Paulo, Brazil
🇧🇷Hospital Erasto Gaertner, Curitiba, Paraná, Brazil
🇧🇷IBCC, São Paulo, Brazil
EDOCH Alternating With DHAP for New Diagnosed Younger MCL
- Conditions
- Mantle Cell Lymphoma
- Interventions
- First Posted Date
- 2016-08-08
- Last Posted Date
- 2019-06-14
- Lead Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Target Recruit Count
- 55
- Registration Number
- NCT02858804
- Locations
- 🇨🇳
Shuhua Yi, Tianjin, China
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
- Conditions
- Transformed Lymphoma / DLBCLDiffuse, Large B-Cell, LymphomaFollicular Lymphoma, Grade 3b
- Interventions
- First Posted Date
- 2016-08-04
- Last Posted Date
- 2019-03-11
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02855359
- Locations
- 🇵🇷
Ponce Medical School Foundation, Ponce, Puerto Rico
🇺🇸Hollings Cancer Center, Charleston, South Carolina, United States
🇺🇸Northwest Medical Specialties, PLLC, Tacoma, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.